10/587975 IAP11 Rec'd PCT/PTO 03 AUG 2006

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Intern	ational	Application No.	:	PCT/EP2005/000388		
International Filing Date			: :	January 17, 2005		
Priori	ty Date((s) Claimed	:	February 4, 2004		
Appli	cant(s)	(DO/EO/US)	:	Philippe GUEDAT et al.		
		ZOLYLIMIDAZOI L TRIGLYCERIDI		TIVES AND THEIR USE AS INHIBITORS OF R PROTEIN		
INFO	ORMA]	TION DISCLOSU	RE STATEM	IENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98		
P.O . 1	Box 145	er for Patents 50 VA 22313-1450				
Sir:						
and 1	This i		re statement i	s made in accordance with 37 C.F.R. §§ 1.56, 1.97		
<u>Timiı</u>	ng and F	<u>Cees</u>				
\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this informat disclosure statement is filed:					
		within three mont under § 1.53(d);	hs of the filin	g date of a national application other than a CPA		
	\boxtimes	within three mon application; OR	ths of the ac	tual filing date of the national phase of a PCT		
		before the mailing RCE).	g of a first sub	stantive office action (including after filing of an		
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the p specified in 37 C.F.R. § 1.97(b), but before the mailing date of:					
			osecution, e.g	R. 1.113; . Ex Parte Quayle, M.P.E.P § 609(B)(2); OR		

10/587975

IAP11 Rec'd PCT/PTO 03 AUG 2006

		is accompanied by:					
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR				
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).				
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:				
		a final	action under 37 C.F.R. § 1.113;				
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);				
		OR a r	notice of allowance under 37 C.F.R. § 1.311;				
	AND:	is filed o	on or before payment of the issue fee; AND is accompanied by:				
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).				
Staten	nents U	nder 37	C.F.R. 1.97(e)				
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or				
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.				
Cited	Materia	<u>ls</u>					
		ancest	or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).				
		_	s of materials listed but not attached were cited in an international search dated April 13, 2005.				
		Not re	quired by 37 CFR § 1.98.				
		Copie	s of the materials listed are attached (except for the foregoing).				

10/587975IAP11 Rec'd PCT/PTO 03 AUG 2006

Non-English Language References

	⊠ [°]	An English-language search report or equivalent paper from a foreign paroffice is provided indicating the relevance of the cited reference(s).			
[A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:			
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 			
		A = document defining the general state of the art O = non-written disclosure P = intercalated document			
		T = document cited to understand the theory or principle underlying the invention			
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date			
		D = cited in the application L = cited for another reason			
		& = publication of member of same patent family			
[Translation of other relevant information on foreign search report			
Other In	nforma	<u>tion</u>			
Paymen	t of Fe	es Due (If Any):			
	A chec	ck for \$ covering the fee identified above is attached.			
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

10/587975 IAP11 Rec'd PCT/PTO 03 AUG 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3216

Date: August 3, 2006

AJZ:hlw

K:\Merck\3000 - 3999\3216\Information Disclosure Statement.doc

10/587975

IAP11 Rec'd PCT/PTO 03 AUG 2006

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.							
Substitute	for form 1449A/PTC)		Complete if Known			
				Application Number	Unassigned		
INFO	RMATION	DIS	CLOSURE	Filing Date	August 3, 2006		
STAT	TEMENT B	Y A	PPLICANT	First Named Inventor	Phillipe GUEDAT et al.		
				Group Art Unit	Unknown		
	(use as many she	ets as	necessary)	Examiner Name	Unknown		
Sheet	1	of	1	Attorney Docket Number	MERCK-3216		

U.S. PATENT DOCUMENTS						
Examiner		U.S. Patent Docu	ment Kind Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document	
Initials *	Cite No.1	Number	(if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY	
					9	
				,		
					·	
	-					
	 					

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ^s (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
	A1	wo	02/42291	Α	Merck Patent GmbH	05-30-2002		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.